A WOMAN who has lost 5.5 stone on Mounjaro in eight months has shared the advice everyone needs to hear. La Hauser, from the ...

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Gov. Phil Murphy's ideas to cut $100 million from the State Health Benefits Program include charging higher co-pays and ...

If you suspect someone has been taking Ozempic, or Mounjaro, or Wegovy, or yet another fat jab, is it impolite to ask them?

US pharma major Eli Lilly has announced top-line results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase III ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

President Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...